Positive News SentimentPositive NewsNASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $13.37 +0.06 (+0.45%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$13.13▼$13.7150-Day Range$10.52▼$15.1252-Week Range$10.29▼$20.23Volume340,736 shsAverage Volume474,207 shsMarket Capitalization$806.56 millionP/E RatioN/ADividend YieldN/APrice Target$45.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pliant Therapeutics alerts: Email Address Pliant Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside239.4% Upside$45.38 Price TargetShort InterestBearish11.54% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews Sentiment1.61Based on 3 Articles This WeekInsider TradingSelling Shares$804,530 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.44) to ($3.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.29 out of 5 starsMedical Sector168th out of 936 stocksPharmaceutical Preparations Industry70th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePliant Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Pliant Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.54% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 0.58%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 3.1 News and Social Media Coverage News SentimentPliant Therapeutics has a news sentiment score of 1.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pliant Therapeutics this week, compared to 3 articles on an average week.Search Interest8 people have searched for PLRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $804,530.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.44) to ($3.71) per share.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 1.69. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Pliant Therapeutics Stock (NASDAQ:PLRX)Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More PLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Stock News HeadlinesJuly 13, 2024 | insidertrades.comPliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette Sells 7,656 SharesJuly 13, 2024 | insidertrades.comKeith Lamont Cummings Sells 10,911 Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) StockJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.July 26 at 2:40 AM | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 18, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Rating Reiterated by Needham & Company LLCJuly 17, 2024 | americanbankingnews.comPliant Therapeutics (NASDAQ:PLRX) Given Buy Rating at HC WainwrightJune 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 13, 2024 | globenewswire.comPliant Therapeutics Announces Appointment of Steve Krognes to Board of DirectorsJuly 27, 2024 | Porter & Company (Ad)Kiss of death from Joe BidenI did not consent. You did not consent. It’s in direct violation of the U.S. Constitution but they do not care.June 12, 2024 | globenewswire.comPliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 6, 2024 | globenewswire.comPliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™May 21, 2024 | globenewswire.comPliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International ConferenceMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pliant Therapeutics on Promising Bexotegrast Trial Results in IPFMay 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Pliant Therapeutics (PLRX), Trevena (TRVN)May 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Tenet Healthcare (THC)May 14, 2024 | msn.comPliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In PatientsMay 14, 2024 | globenewswire.comPliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary FibrosisMay 8, 2024 | markets.businessinsider.comPliant Therapeutics: Advancing Trials and Diversifying Pipeline Justify Buy RatingSee More Headlines Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$45.38 High Stock Price Target$63.00 Low Stock Price Target$36.00 Potential Upside/Downside+239.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,340,000.00 Net MarginsN/A Pretax Margin-68,847.98% Return on Equity-35.08% Return on Assets-31.78% Debt Debt-to-Equity Ratio0.07 Current Ratio16.12 Quick Ratio16.12 Sales & Book Value Annual Sales$248,000.00 Price / Sales3,252.25 Cash FlowN/A Price / Cash FlowN/A Book Value$7.91 per share Price / Book1.69Miscellaneous Outstanding Shares60,326,000Free Float56,465,000Market Cap$806.56 million OptionableOptionable Beta1.16 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Bernard Coulie M.B.A. (Age 57)M.D., Ph.D., President, CEO & Director Comp: $996.97kDr. Keith Lamont Cummings M.B.A. (Age 47)M.D., Chief Financial Officer Comp: $684.14kMr. Mike Ouimette J.D. (Age 51)General Counsel & Corporate Secretary Comp: $606.03kMr. Johannes P. Hull (Age 49)Chief Business Officer Comp: $602.51kDr. Éric Lefebvre M.D. (Age 60)Chief Medical Officer Comp: $734.41kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsAnnexonNASDAQ:ANNXFibroGenNASDAQ:FGENAmicus TherapeuticsNASDAQ:FOLDRhythm PharmaceuticalsNASDAQ:RYTMACADIA PharmaceuticalsNASDAQ:ACADView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 29,629 shares on 7/26/2024Ownership: 0.379%Summit Securities Group LLCBought 5,532 shares on 7/26/2024Ownership: 0.009%Hennion & Walsh Asset Management Inc.Bought 68,289 shares on 7/20/2024Ownership: 0.113%SG Americas Securities LLCBought 38,679 shares on 7/12/2024Ownership: 0.076%Bernard CoulieSold 38,710 sharesTotal: $447,487.60 ($11.56/share)View All Insider TransactionsView All Institutional Transactions PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $18.11 at the beginning of the year. Since then, PLRX stock has decreased by 26.2% and is now trading at $13.37. View the best growth stocks for 2024 here. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) posted its quarterly earnings results on Monday, May, 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by $0.02. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Top institutional investors of Pliant Therapeutics include Bank of New York Mellon Corp (0.38%), Hennion & Walsh Asset Management Inc. (0.11%), SG Americas Securities LLC (0.08%) and Harbor Capital Advisors Inc. (0.05%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT) and Archer-Daniels-Midland (ADM). This page (NASDAQ:PLRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
